View Future GrowthCorbion 과거 순이익 실적과거 기준 점검 4/6Corbion의 수입은 연평균 -11.1%의 비율로 감소해 온 반면, Chemicals 산업은 수입이 연평균 3% 증가했습니다. 매출은 연평균 4.5%의 비율로 증가해 왔습니다. Corbion의 자기자본이익률은 10.1%이고 순이익률은 5.9%입니다.핵심 정보-11.08%순이익 성장률-10.79%주당순이익(EPS) 성장률Chemicals 산업 성장률4.35%매출 성장률4.46%자기자본이익률10.07%순이익률5.90%다음 순이익 업데이트31 Jul 2026최근 과거 실적 업데이트Reported Earnings • Mar 02Full year 2025 earnings released: EPS: €1.29 (vs €0.79 in FY 2024)Full year 2025 results: EPS: €1.29 (up from €0.79 in FY 2024). Revenue: €1.27b (down 1.6% from FY 2024). Net income: €74.8m (up 63% from FY 2024). Profit margin: 5.9% (up from 3.6% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.공시 • Oct 09+ 2 more updatesCorbion N.V. to Report Fiscal Year 2025 Results on Feb 26, 2026Corbion N.V. announced that they will report fiscal year 2025 results on Feb 26, 2026Reported Earnings • Aug 05First half 2025 earnings released: EPS: €0.73 (vs €0.39 in 1H 2024)First half 2025 results: EPS: €0.73 (up from €0.39 in 1H 2024). Revenue: €645.6m (up 1.3% from 1H 2024). Net income: €42.4m (up 87% from 1H 2024). Profit margin: 6.6% (up from 3.6% in 1H 2024). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 28Full year 2024 earnings released: EPS: €0.79 (vs €1.23 in FY 2023)Full year 2024 results: EPS: €0.79 (down from €1.23 in FY 2023). Revenue: €1.29b (down 11% from FY 2023). Net income: €45.9m (down 37% from FY 2023). Profit margin: 3.6% (down from 5.0% in FY 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 3.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.공시 • Oct 25+ 1 more updateCorbion N.V. to Report Q2, 2025 Results on Jul 31, 2025Corbion N.V. announced that they will report Q2, 2025 results on Jul 31, 2025Reported Earnings • Aug 12First half 2024 earnings released: EPS: €0.39 (vs €0.26 in 1H 2023)First half 2024 results: EPS: €0.39 (up from €0.26 in 1H 2023). Revenue: €637.1m (flat on 1H 2023). Net income: €22.7m (up 47% from 1H 2023). Profit margin: 3.6% (up from 2.4% in 1H 2023). Revenue is forecast to stay flat during the next 3 years compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.모든 업데이트 보기Recent updates공시 • May 15Corbion N.V. Approves Special Dividend for the Financial Year 2025, Payable on 22 May 2026Corbion N.V. at the Annual General Shareholders Meeting held on 13 May 2026 approved dividend of €1.00 per share comprising a special dividend of €0.36 per share for the financial year 2025. Dividend will be all-cash and will in principle be subject to Dutch dividend withholding tax of 15%. The ex-dividend date is 15 May 2026, the record date is 18 May 2026, and the payment date is 22 May 2026.공시 • May 14+ 1 more updateCorbion N.V. Approves Regular Dividend for the Financial Year 2025, Payable on 22 May 2026Corbion N.V. at the Annual General Shareholders Meeting held on 13 May 2026 approved dividend of €1.00 per share comprising a regular dividend of €0.64 per share for the financial year 2025. Dividend will be all-cash and will in principle be subject to Dutch dividend withholding tax of 15%. The ex-dividend date is 15 May 2026, the record date is 18 May 2026, and the payment date is 22 May 2026.Upcoming Dividend • May 08Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 15 May 2026. Payment date: 22 May 2026. Payout ratio is a comfortable 50% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (3.9%).공시 • Apr 24Corbion N.V. Affirms Earnings Guidance for Fiscal Year 2026Corbion N.V. affirmed earnings guidance for Fiscal Year 2026. For the period, the company expects to deliver guidance on all forecasted metrics, including sales growth.Declared Dividend • Apr 06Dividend of €1.00 announcedShareholders will receive a dividend of €1.00. Ex-date: 15th May 2026 Payment date: 22nd May 2026 Dividend yield will be 5.3%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (50% earnings payout ratio) and cash flows (40% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 33% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Mar 02Full year 2025 earnings released: EPS: €1.29 (vs €0.79 in FY 2024)Full year 2025 results: EPS: €1.29 (up from €0.79 in FY 2024). Revenue: €1.27b (down 1.6% from FY 2024). Net income: €74.8m (up 63% from FY 2024). Profit margin: 5.9% (up from 3.6% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.공시 • Feb 27Corbion N.V., Annual General Meeting, May 13, 2026Corbion N.V., Annual General Meeting, May 13, 2026.공시 • Feb 26+ 1 more updateCorbion N.V. Proposes Dividend for the Year 2025Corbion N.V. proposed to distribute regular dividend of €0.64 per share for 2025.공시 • Oct 09+ 2 more updatesCorbion N.V. to Report Fiscal Year 2025 Results on Feb 26, 2026Corbion N.V. announced that they will report fiscal year 2025 results on Feb 26, 2026Reported Earnings • Aug 05First half 2025 earnings released: EPS: €0.73 (vs €0.39 in 1H 2024)First half 2025 results: EPS: €0.73 (up from €0.39 in 1H 2024). Revenue: €645.6m (up 1.3% from 1H 2024). Net income: €42.4m (up 87% from 1H 2024). Profit margin: 6.6% (up from 3.6% in 1H 2024). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.Upcoming Dividend • May 09Upcoming dividend of €0.64 per shareEligible shareholders must have bought the stock before 16 May 2025. Payment date: 27 May 2025. Payout ratio is on the higher end at 81%, however this is supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (4.4%).Declared Dividend • Apr 04Final dividend of €0.64 announcedShareholders will receive a dividend of €0.64. Ex-date: 16th May 2025 Payment date: 27th May 2025 Dividend yield will be 3.4%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (81% earnings payout ratio) and cash flows (37% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 108% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • Apr 03Corbion N.V. announces Annual dividend, payable on May 27, 2025Corbion N.V. announced Annual dividend of EUR 0.6400 per share payable on May 27, 2025, ex-date on May 16, 2025 and record date on May 19, 2025.Reported Earnings • Feb 28Full year 2024 earnings released: EPS: €0.79 (vs €1.23 in FY 2023)Full year 2024 results: EPS: €0.79 (down from €1.23 in FY 2023). Revenue: €1.29b (down 11% from FY 2023). Net income: €45.9m (down 37% from FY 2023). Profit margin: 3.6% (down from 5.0% in FY 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 3.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.공시 • Feb 28Corbion N.V., Annual General Meeting, May 14, 2025Corbion N.V., Annual General Meeting, May 14, 2025.공시 • Feb 27Corbion N.V. Proposes Regular Cash DividendCorbion N.V. proposed a regular cash dividend increase of +5% to €0.64 per ordinary share to be submitted for approval to the annual General Meeting of Shareholders.Buy Or Sell Opportunity • Feb 12Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 1.5% to €22.68. The fair value is estimated to be €18.55, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 12%. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are also forecast to grow by 10% per annum over the same time period.Buy Or Sell Opportunity • Jan 02Now 20% overvaluedOver the last 90 days, the stock has fallen 12% to €21.64. The fair value is estimated to be €17.96, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to decline by 4.8% in 2 years. Earnings are forecast to grow by 20% in the next 2 years.Buy Or Sell Opportunity • Oct 31Now 24% undervaluedOver the last 90 days, the stock has risen 13% to €23.24. The fair value is estimated to be €30.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to decline by 5.2% in 2 years. Earnings are forecast to grow by 15% in the next 2 years.New Risk • Oct 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.5% per year for the foreseeable future. Minor Risks High level of debt (51% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.공시 • Oct 25+ 1 more updateCorbion N.V. to Report Q2, 2025 Results on Jul 31, 2025Corbion N.V. announced that they will report Q2, 2025 results on Jul 31, 2025Reported Earnings • Aug 12First half 2024 earnings released: EPS: €0.39 (vs €0.26 in 1H 2023)First half 2024 results: EPS: €0.39 (up from €0.26 in 1H 2023). Revenue: €637.1m (flat on 1H 2023). Net income: €22.7m (up 47% from 1H 2023). Profit margin: 3.6% (up from 2.4% in 1H 2023). Revenue is forecast to stay flat during the next 3 years compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.Buy Or Sell Opportunity • Jun 14Now 20% undervaluedOver the last 90 days, the stock has risen 2.0% to €19.65. The fair value is estimated to be €24.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 9.7%. For the next 3 years, revenue is forecast to grow by 0.3% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.Declared Dividend • May 03Final dividend of €0.61 announcedShareholders will receive a dividend of €0.61. Ex-date: 17th May 2024 Payment date: 28th May 2024 Dividend yield will be 3.4%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by earnings (49% earnings payout ratio) but not covered by cash flows (224% cash payout ratio). The dividend has increased by an average of 15% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 54% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • Apr 12Corbion Appoints Masha Vis-Mertens as Chief Human Resources Officer and Member of the Executive Committee as of 1 May 2024Corbion announced appointment of Masha Vis-Mertens as Chief Human Resources Officer and member of the Executive Committee as of 1 May 2024. Masha Vis-Mertens, a Dutch national, joins Corbion from Switzerland where she was most recently Chief Human Resources Officer of Barry Callebaut, a global Cocoa and Chocolate Manufacturer. Over her career, she has lived in various regions and countries and has been a successful leader in HR, Commercial and Supply Chain roles. In her previous positions she gained a wealth of experience in talent development, diversity and inclusion, culture, and organizational transformation that she will be bringing to Corbion. Masha brings a diverse and multi-cultural background and a fresh perspective. She worked internationally throughout her career and is fluent in Dutch, German, French and English.공시 • Apr 03Kingswood Capital Management, L.P. completed the acquisition of Emulsifiers business from Corbion N.V.Kingswood Capital Management, L.P. singed a binding agreement to acquire Emulsifiers business from Corbion N.V for $362 million on January 26, 2024. The purchase price paid for the business is $362 million with expected net cash proceeds of approximately $275 million, post tax and transaction costs. The sale, which is contingent upon the satisfaction of certain conditions, including regulatory approvals and transaction is expected to close in the second quarter of this year. Kirkland & Ellis LLP acted as legal advisor and Configure Partners, LLC acted as debt advisor to Kingswood Capital Management, L.P. Lazard B.V. acted as financial advisor and Stinson LLP acted as legal advisor to Corbion N.V. Kingswood Capital Management, L.P. completed the acquisition of Emulsifiers business from Corbion N.V on April 2, 2024. The emulsifiers business, moving forward, will operate under the name PATCO Products, LLC and Vice President of Emulsifiers at Corbion, John Miller, will continue to lead the Company as its Chief Executive Officer.Valuation Update With 7 Day Price Move • Mar 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €20.66, the stock trades at a forward P/E ratio of 23x. Average trailing P/E is 18x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €18.33 per share.공시 • Mar 05Corbion Announces Preliminary Results of New Study from Millennial Salmon ProjectCorbion announced preliminary results of a new study from the Millennial Salmon Project, a strategic partnership among organizations along the value chain of salmon production. Conducted by Nofima and recently published in Aquaculture, the study confirms that AlgaPrime™ DHA can be added at varying levels without negatively impacting feed quality, and actually promoting a more stable process and pellet quality. Primarily funded by the Research Council of Norway and made up of leading organizations Nofima, InnovaFeed, Corbion,Cargill, MOWI, Labeyrie Fine Foods, SINTEF Ocean and Auchan, the Millennial Salmon Project aims to create the world’s most sustainable farmed salmon using novel ingredients with a low carbon footprint and a focus on the circular economy. The first round of research sought to determine optimal inclusion levels of AlgaPrime™ DHA LS — Corbion’s algae-based omega-3 DHA-rich ingredient in liquid suspension — in feed for Atlantic salmon, evaluating the ingredient’s effect on the feed production process. Variables examined included: physical pellet quality, expansion parameters and microstructure and later its digestibility. AlgaPrime™ DHA can be incorporated at two different moments in the feed production process: into the mix prior to extrusion and during pellet coating. Therefore, the maximum levels of AlgaPrime™ DHA inclusion in both moments was studied. An array of diets was produced and tested, from a control feed using fish meal and soy protein concentrate to feeds with the high inclusion levels of AlgaPrime™ DHA LS. Applying a method that enables numerous comparisons, researchers determined that inclusion of 100 g/kg AlgaPrime™ DHA LS in the mixture was commercially interesting, considering the levels of lipids mostly used in the feed mix. Based on the industry standard practices, researchers tested AlgaPrime™ DHA LS in the pellet coating process and were able to add up to 14% inclusion in a final feed with 36% lipids, which is far above the relevant industrial application levels of omega-3. In a uncommon study design that combines the technical application and nutrition science and after the feed production trials, the research group then looked at four diets containing AlgaPrime™ DHA in the mix, the coating, and a combination of the two, using AlgaPrime™ DHA LS at 10% and 20% inclusions. All four diets showed high nutrient digestibility in Atlantic salmon. For reference, with the inclusion of 8% of AlgaPrime™ DHA LS is possible to replace a 10% inclusion of fish oil in diets with the same omega-3 levels. These findings represent an important step for fish nutrition, illustrating the viability of sustainability gains by increasing the use of ingredients with high concentrations of omega-3, something a reliance on fish oil alone could not accomplish. At the same time, it is great news to the aquaculture industry, enabling the strategic management of omega-3 levels in feed to facilitate the production growth, a much-needed tool in view of increasing pressure on oceans and the supply gap of traditional marine resources. AlgaPrime™ DHA LS is made from a single-cell algae strain grown at scale using industrial fermentation to produce DHA while ensuring feasibility for feed manufacturers and salmon producers. With a higher DHA concentration compared to fish oil and other alternatives, inclusion of AlgaPrime™ DHA LS in feed can maintain or raise omega-3 levels in healthy diets, reducing the dependency for fish oil, thereby helping to preserve the environment.Declared Dividend • Mar 04Dividend of €0.61 announcedShareholders will receive a dividend of €0.61. Ex-date: 19th May 2024 Payment date: 30th May 2024 Dividend yield will be 3.2%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by earnings (50% earnings payout ratio) but not covered by cash flows (206% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Mar 02Full year 2023 earnings released: EPS: €1.23 (vs €1.53 in FY 2022)Full year 2023 results: EPS: €1.23 (down from €1.53 in FY 2022). Revenue: €1.44b (down 1.0% from FY 2022). Net income: €72.9m (down 19% from FY 2022). Profit margin: 5.0% (down from 6.2% in FY 2022). Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 3.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.Valuation Update With 7 Day Price Move • Jan 27Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €19.43, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 18x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 58% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €10.43 per share.Valuation Update With 7 Day Price Move • Dec 20Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €19.06, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 56% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.36 per share.공시 • Nov 21+ 2 more updatesCorbion N.V. to Report Fiscal Year 2023 Results on Mar 01, 2024Corbion N.V. announced that they will report fiscal year 2023 results on Mar 01, 2024Buying Opportunity • Oct 20Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be €21.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 8.1%. Revenue is forecast to grow by 7.1% in 2 years. Earnings is forecast to grow by 48% in the next 2 years.Reported Earnings • Aug 11First half 2023 earnings released: EPS: €0.48 (vs €0.88 in 1H 2022)First half 2023 results: EPS: €0.48 (down from €0.88 in 1H 2022). Revenue: €738.0m (up 7.4% from 1H 2022). Net income: €28.1m (down 46% from 1H 2022). Profit margin: 3.8% (down from 7.5% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jun 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €21.63, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.24 per share.공시 • May 18Corbion N.V. Approves Dividend for the Year 2022, Payable on 30 May 2023Corbion N.V. announced that General Shareholders Meeting held on 17 May 2023 approved dividend of €0.56 per ordinary share for the financial year 2022 was also approved. Dividends will be all-cash and will in principle be subject to Dutch dividend withholding tax of 15%. The ex-dividend date is 19 May 2023, the record date is 22 May 2023, and the payment day is 30 May 2023.Upcoming Dividend • May 12Upcoming dividend of €0.56 per share at 1.9% yieldEligible shareholders must have bought the stock before 19 May 2023. Payment date: 30 May 2023. Payout ratio is a comfortable 37% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.3%).Recent Insider Transactions • May 08Insider recently bought €142k worth of stockOn the 3rd of May, O.Y.A.R Rigaud bought around 5k shares on-market at roughly €28.37 per share. This transaction amounted to 5.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €259k more in shares than they have sold in the last 12 months.Reported Earnings • Mar 04Full year 2022 earnings released: EPS: €1.53 (vs €1.33 in FY 2021)Full year 2022 results: EPS: €1.53 (up from €1.33 in FY 2021). Revenue: €1.46b (up 36% from FY 2021). Net income: €90.0m (up 15% from FY 2021). Profit margin: 6.2% (down from 7.3% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.공시 • Dec 13+ 1 more updateCorbion N.V. to Report Fiscal Year 2022 Results on Mar 03, 2023Corbion N.V. announced that they will report fiscal year 2022 results on Mar 03, 2023Buying Opportunity • Oct 05Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €32.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.4% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 17% in 2 years. Earnings is forecast to grow by 59% in the next 2 years.Buying Opportunity • Sep 20Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be €32.35, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.4% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 16% in 2 years. Earnings is forecast to grow by 59% in the next 2 years.Reported Earnings • Aug 11First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down €67.5m from profit in 1H 2021). Profit margin: (down from 13% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 7.9% compared to a 21% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jul 21Investor sentiment improved over the past weekAfter last week's 17% share price gain to €33.18, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 18x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €35.74 per share.Buying Opportunity • Jul 05Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 9.2%. The fair value is estimated to be €35.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 9.3% per annum. Earnings is also forecast to grow by 9.9% per annum over the same time period.Upcoming Dividend • May 13Upcoming dividend of €0.56 per shareEligible shareholders must have bought the stock before 20 May 2022. Payment date: 31 May 2022. Payout ratio is a comfortable 42% but the company is not cash flow positive. Trailing yield: 1.7%. Lower than top quartile of British dividend payers (4.8%). Lower than average of industry peers (2.7%).Reported Earnings • Feb 26Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: €1.33 (up from €1.24 in FY 2020). Revenue: €1.07b (up 8.5% from FY 2020). Net income: €78.3m (up 7.1% from FY 2020). Profit margin: 7.3% (down from 7.4% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 11% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 13First half 2021 earnings released: EPS €1.15 (vs €0.42 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €515.6m (up 4.8% from 1H 2020). Net income: €67.5m (up 173% from 1H 2020). Profit margin: 13% (up from 5.0% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 19% per year.Executive Departure • May 26Member of the Supervisory Board has left the companyOn the 19th of May, Jack de Kreij's tenure as Member of the Supervisory Board ended after 10.1 years in the role. We don't have any record of a personal shareholding under Jack's name. A total of 2 executives have left over the last 12 months.Upcoming Dividend • May 14Upcoming dividend of €0.56 per shareEligible shareholders must have bought the stock before 21 May 2021. Payment date: 01 June 2021. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (4.1%). Lower than average of industry peers (1.6%).Analyst Estimate Surprise Post Earnings • Mar 07Revenue misses expectationsRevenue missed analyst estimates by 0.6%. Over the next year, revenue is forecast to grow 1.9% compared to a 9.0% decline forecast for the Chemicals industry in the United Kingdom.Reported Earnings • Mar 07Full year 2020 earnings released: EPS €1.24 (vs €0.44 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €986.5m (up 1.0% from FY 2019). Net income: €73.1m (up 183% from FY 2019). Profit margin: 7.4% (up from 2.6% in FY 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Jan 30New 90-day high: €48.10The company is up 23% from its price of €38.95 on 30 October 2020. The British market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €119 per share.Is New 90 Day High Low • Jan 04New 90-day high: €46.80The company is up 10.0% from its price of €42.65 on 06 October 2020. The British market is also up 10.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €110 per share.Is New 90 Day High Low • Dec 19New 90-day high: €46.05The company is up 25% from its price of €36.95 on 18 September 2020. The British market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €109 per share.Is New 90 Day High Low • Dec 03New 90-day high: €44.10The company is up 20% from its price of €36.85 on 04 September 2020. The British market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €94.58 per share.Is New 90 Day High Low • Sep 30New 90-day high: €39.45The company is up 22% from its price of €32.30 on 02 July 2020. The British market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.75 per share.매출 및 비용 세부 내역Corbion가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이LSE:0QHL 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Dec 251,267751744330 Sep 251,282701784430 Jun 251,297661824531 Mar 251,292561824531 Dec 241,288461834630 Sep 241,274481804630 Jun 241,260501774531 Mar 241,262471764531 Dec 231,264431764630 Sep 231,338481784730 Jun 231,412541804831 Mar 231,435721764831 Dec 221,458901714730 Sep 221,350761674630 Jun 221,243631624631 Mar 221,157701584431 Dec 211,071781554330 Sep 211,040971494130 Jun 211,0101161444031 Mar 21998951423831 Dec 20987731403730 Sep 20992491433530 Jun 20997241473231 Mar 20987251473331 Dec 19976261463530 Sep 19953371413830 Jun 19930481354231 Mar 19914511324131 Dec 18897541293930 Sep 18883611283730 Jun 18869691263531 Mar 18880771263431 Dec 17892851263330 Sep 17905871283230 Jun 17918891303231 Mar 17914951283131 Dec 169111021263130 Sep 169171031243330 Jun 169221041223431 Mar 16920911223331 Dec 15918781213330 Sep 15885451193230 Jun 158511311831양질의 수익: 0QHL는 고품질 수익을 보유하고 있습니다.이익 마진 증가: 0QHL의 현재 순 이익률 (5.9%)은 지난해 (3.6%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 0QHL의 수익은 지난 5년 동안 연평균 11.1% 감소했습니다.성장 가속화: 지난 1년간 0QHL 의 수익 증가율(63%)은 연간 평균(-11.1%)을 초과합니다.수익 대 산업: 0QHL의 지난 1년 수익 증가율(63%)은 Chemicals 업계의 -59.9%를 상회했습니다.자기자본이익률높은 ROE: 0QHL의 자본 수익률(10.1%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 05:47종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Corbion N.V.는 13명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Setu ShardaBarclaysSebastian BrayBerenbergFintan RyanBerenberg10명의 분석가 더 보기
Reported Earnings • Mar 02Full year 2025 earnings released: EPS: €1.29 (vs €0.79 in FY 2024)Full year 2025 results: EPS: €1.29 (up from €0.79 in FY 2024). Revenue: €1.27b (down 1.6% from FY 2024). Net income: €74.8m (up 63% from FY 2024). Profit margin: 5.9% (up from 3.6% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
공시 • Oct 09+ 2 more updatesCorbion N.V. to Report Fiscal Year 2025 Results on Feb 26, 2026Corbion N.V. announced that they will report fiscal year 2025 results on Feb 26, 2026
Reported Earnings • Aug 05First half 2025 earnings released: EPS: €0.73 (vs €0.39 in 1H 2024)First half 2025 results: EPS: €0.73 (up from €0.39 in 1H 2024). Revenue: €645.6m (up 1.3% from 1H 2024). Net income: €42.4m (up 87% from 1H 2024). Profit margin: 6.6% (up from 3.6% in 1H 2024). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 28Full year 2024 earnings released: EPS: €0.79 (vs €1.23 in FY 2023)Full year 2024 results: EPS: €0.79 (down from €1.23 in FY 2023). Revenue: €1.29b (down 11% from FY 2023). Net income: €45.9m (down 37% from FY 2023). Profit margin: 3.6% (down from 5.0% in FY 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 3.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.
공시 • Oct 25+ 1 more updateCorbion N.V. to Report Q2, 2025 Results on Jul 31, 2025Corbion N.V. announced that they will report Q2, 2025 results on Jul 31, 2025
Reported Earnings • Aug 12First half 2024 earnings released: EPS: €0.39 (vs €0.26 in 1H 2023)First half 2024 results: EPS: €0.39 (up from €0.26 in 1H 2023). Revenue: €637.1m (flat on 1H 2023). Net income: €22.7m (up 47% from 1H 2023). Profit margin: 3.6% (up from 2.4% in 1H 2023). Revenue is forecast to stay flat during the next 3 years compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.
공시 • May 15Corbion N.V. Approves Special Dividend for the Financial Year 2025, Payable on 22 May 2026Corbion N.V. at the Annual General Shareholders Meeting held on 13 May 2026 approved dividend of €1.00 per share comprising a special dividend of €0.36 per share for the financial year 2025. Dividend will be all-cash and will in principle be subject to Dutch dividend withholding tax of 15%. The ex-dividend date is 15 May 2026, the record date is 18 May 2026, and the payment date is 22 May 2026.
공시 • May 14+ 1 more updateCorbion N.V. Approves Regular Dividend for the Financial Year 2025, Payable on 22 May 2026Corbion N.V. at the Annual General Shareholders Meeting held on 13 May 2026 approved dividend of €1.00 per share comprising a regular dividend of €0.64 per share for the financial year 2025. Dividend will be all-cash and will in principle be subject to Dutch dividend withholding tax of 15%. The ex-dividend date is 15 May 2026, the record date is 18 May 2026, and the payment date is 22 May 2026.
Upcoming Dividend • May 08Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 15 May 2026. Payment date: 22 May 2026. Payout ratio is a comfortable 50% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (3.9%).
공시 • Apr 24Corbion N.V. Affirms Earnings Guidance for Fiscal Year 2026Corbion N.V. affirmed earnings guidance for Fiscal Year 2026. For the period, the company expects to deliver guidance on all forecasted metrics, including sales growth.
Declared Dividend • Apr 06Dividend of €1.00 announcedShareholders will receive a dividend of €1.00. Ex-date: 15th May 2026 Payment date: 22nd May 2026 Dividend yield will be 5.3%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (50% earnings payout ratio) and cash flows (40% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 33% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Mar 02Full year 2025 earnings released: EPS: €1.29 (vs €0.79 in FY 2024)Full year 2025 results: EPS: €1.29 (up from €0.79 in FY 2024). Revenue: €1.27b (down 1.6% from FY 2024). Net income: €74.8m (up 63% from FY 2024). Profit margin: 5.9% (up from 3.6% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
공시 • Feb 27Corbion N.V., Annual General Meeting, May 13, 2026Corbion N.V., Annual General Meeting, May 13, 2026.
공시 • Feb 26+ 1 more updateCorbion N.V. Proposes Dividend for the Year 2025Corbion N.V. proposed to distribute regular dividend of €0.64 per share for 2025.
공시 • Oct 09+ 2 more updatesCorbion N.V. to Report Fiscal Year 2025 Results on Feb 26, 2026Corbion N.V. announced that they will report fiscal year 2025 results on Feb 26, 2026
Reported Earnings • Aug 05First half 2025 earnings released: EPS: €0.73 (vs €0.39 in 1H 2024)First half 2025 results: EPS: €0.73 (up from €0.39 in 1H 2024). Revenue: €645.6m (up 1.3% from 1H 2024). Net income: €42.4m (up 87% from 1H 2024). Profit margin: 6.6% (up from 3.6% in 1H 2024). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
Upcoming Dividend • May 09Upcoming dividend of €0.64 per shareEligible shareholders must have bought the stock before 16 May 2025. Payment date: 27 May 2025. Payout ratio is on the higher end at 81%, however this is supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (4.4%).
Declared Dividend • Apr 04Final dividend of €0.64 announcedShareholders will receive a dividend of €0.64. Ex-date: 16th May 2025 Payment date: 27th May 2025 Dividend yield will be 3.4%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (81% earnings payout ratio) and cash flows (37% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 108% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • Apr 03Corbion N.V. announces Annual dividend, payable on May 27, 2025Corbion N.V. announced Annual dividend of EUR 0.6400 per share payable on May 27, 2025, ex-date on May 16, 2025 and record date on May 19, 2025.
Reported Earnings • Feb 28Full year 2024 earnings released: EPS: €0.79 (vs €1.23 in FY 2023)Full year 2024 results: EPS: €0.79 (down from €1.23 in FY 2023). Revenue: €1.29b (down 11% from FY 2023). Net income: €45.9m (down 37% from FY 2023). Profit margin: 3.6% (down from 5.0% in FY 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 3.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.
공시 • Feb 28Corbion N.V., Annual General Meeting, May 14, 2025Corbion N.V., Annual General Meeting, May 14, 2025.
공시 • Feb 27Corbion N.V. Proposes Regular Cash DividendCorbion N.V. proposed a regular cash dividend increase of +5% to €0.64 per ordinary share to be submitted for approval to the annual General Meeting of Shareholders.
Buy Or Sell Opportunity • Feb 12Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 1.5% to €22.68. The fair value is estimated to be €18.55, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 12%. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are also forecast to grow by 10% per annum over the same time period.
Buy Or Sell Opportunity • Jan 02Now 20% overvaluedOver the last 90 days, the stock has fallen 12% to €21.64. The fair value is estimated to be €17.96, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to decline by 4.8% in 2 years. Earnings are forecast to grow by 20% in the next 2 years.
Buy Or Sell Opportunity • Oct 31Now 24% undervaluedOver the last 90 days, the stock has risen 13% to €23.24. The fair value is estimated to be €30.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to decline by 5.2% in 2 years. Earnings are forecast to grow by 15% in the next 2 years.
New Risk • Oct 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.5% per year for the foreseeable future. Minor Risks High level of debt (51% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
공시 • Oct 25+ 1 more updateCorbion N.V. to Report Q2, 2025 Results on Jul 31, 2025Corbion N.V. announced that they will report Q2, 2025 results on Jul 31, 2025
Reported Earnings • Aug 12First half 2024 earnings released: EPS: €0.39 (vs €0.26 in 1H 2023)First half 2024 results: EPS: €0.39 (up from €0.26 in 1H 2023). Revenue: €637.1m (flat on 1H 2023). Net income: €22.7m (up 47% from 1H 2023). Profit margin: 3.6% (up from 2.4% in 1H 2023). Revenue is forecast to stay flat during the next 3 years compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.
Buy Or Sell Opportunity • Jun 14Now 20% undervaluedOver the last 90 days, the stock has risen 2.0% to €19.65. The fair value is estimated to be €24.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has declined by 9.7%. For the next 3 years, revenue is forecast to grow by 0.3% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.
Declared Dividend • May 03Final dividend of €0.61 announcedShareholders will receive a dividend of €0.61. Ex-date: 17th May 2024 Payment date: 28th May 2024 Dividend yield will be 3.4%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by earnings (49% earnings payout ratio) but not covered by cash flows (224% cash payout ratio). The dividend has increased by an average of 15% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 54% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • Apr 12Corbion Appoints Masha Vis-Mertens as Chief Human Resources Officer and Member of the Executive Committee as of 1 May 2024Corbion announced appointment of Masha Vis-Mertens as Chief Human Resources Officer and member of the Executive Committee as of 1 May 2024. Masha Vis-Mertens, a Dutch national, joins Corbion from Switzerland where she was most recently Chief Human Resources Officer of Barry Callebaut, a global Cocoa and Chocolate Manufacturer. Over her career, she has lived in various regions and countries and has been a successful leader in HR, Commercial and Supply Chain roles. In her previous positions she gained a wealth of experience in talent development, diversity and inclusion, culture, and organizational transformation that she will be bringing to Corbion. Masha brings a diverse and multi-cultural background and a fresh perspective. She worked internationally throughout her career and is fluent in Dutch, German, French and English.
공시 • Apr 03Kingswood Capital Management, L.P. completed the acquisition of Emulsifiers business from Corbion N.V.Kingswood Capital Management, L.P. singed a binding agreement to acquire Emulsifiers business from Corbion N.V for $362 million on January 26, 2024. The purchase price paid for the business is $362 million with expected net cash proceeds of approximately $275 million, post tax and transaction costs. The sale, which is contingent upon the satisfaction of certain conditions, including regulatory approvals and transaction is expected to close in the second quarter of this year. Kirkland & Ellis LLP acted as legal advisor and Configure Partners, LLC acted as debt advisor to Kingswood Capital Management, L.P. Lazard B.V. acted as financial advisor and Stinson LLP acted as legal advisor to Corbion N.V. Kingswood Capital Management, L.P. completed the acquisition of Emulsifiers business from Corbion N.V on April 2, 2024. The emulsifiers business, moving forward, will operate under the name PATCO Products, LLC and Vice President of Emulsifiers at Corbion, John Miller, will continue to lead the Company as its Chief Executive Officer.
Valuation Update With 7 Day Price Move • Mar 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €20.66, the stock trades at a forward P/E ratio of 23x. Average trailing P/E is 18x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €18.33 per share.
공시 • Mar 05Corbion Announces Preliminary Results of New Study from Millennial Salmon ProjectCorbion announced preliminary results of a new study from the Millennial Salmon Project, a strategic partnership among organizations along the value chain of salmon production. Conducted by Nofima and recently published in Aquaculture, the study confirms that AlgaPrime™ DHA can be added at varying levels without negatively impacting feed quality, and actually promoting a more stable process and pellet quality. Primarily funded by the Research Council of Norway and made up of leading organizations Nofima, InnovaFeed, Corbion,Cargill, MOWI, Labeyrie Fine Foods, SINTEF Ocean and Auchan, the Millennial Salmon Project aims to create the world’s most sustainable farmed salmon using novel ingredients with a low carbon footprint and a focus on the circular economy. The first round of research sought to determine optimal inclusion levels of AlgaPrime™ DHA LS — Corbion’s algae-based omega-3 DHA-rich ingredient in liquid suspension — in feed for Atlantic salmon, evaluating the ingredient’s effect on the feed production process. Variables examined included: physical pellet quality, expansion parameters and microstructure and later its digestibility. AlgaPrime™ DHA can be incorporated at two different moments in the feed production process: into the mix prior to extrusion and during pellet coating. Therefore, the maximum levels of AlgaPrime™ DHA inclusion in both moments was studied. An array of diets was produced and tested, from a control feed using fish meal and soy protein concentrate to feeds with the high inclusion levels of AlgaPrime™ DHA LS. Applying a method that enables numerous comparisons, researchers determined that inclusion of 100 g/kg AlgaPrime™ DHA LS in the mixture was commercially interesting, considering the levels of lipids mostly used in the feed mix. Based on the industry standard practices, researchers tested AlgaPrime™ DHA LS in the pellet coating process and were able to add up to 14% inclusion in a final feed with 36% lipids, which is far above the relevant industrial application levels of omega-3. In a uncommon study design that combines the technical application and nutrition science and after the feed production trials, the research group then looked at four diets containing AlgaPrime™ DHA in the mix, the coating, and a combination of the two, using AlgaPrime™ DHA LS at 10% and 20% inclusions. All four diets showed high nutrient digestibility in Atlantic salmon. For reference, with the inclusion of 8% of AlgaPrime™ DHA LS is possible to replace a 10% inclusion of fish oil in diets with the same omega-3 levels. These findings represent an important step for fish nutrition, illustrating the viability of sustainability gains by increasing the use of ingredients with high concentrations of omega-3, something a reliance on fish oil alone could not accomplish. At the same time, it is great news to the aquaculture industry, enabling the strategic management of omega-3 levels in feed to facilitate the production growth, a much-needed tool in view of increasing pressure on oceans and the supply gap of traditional marine resources. AlgaPrime™ DHA LS is made from a single-cell algae strain grown at scale using industrial fermentation to produce DHA while ensuring feasibility for feed manufacturers and salmon producers. With a higher DHA concentration compared to fish oil and other alternatives, inclusion of AlgaPrime™ DHA LS in feed can maintain or raise omega-3 levels in healthy diets, reducing the dependency for fish oil, thereby helping to preserve the environment.
Declared Dividend • Mar 04Dividend of €0.61 announcedShareholders will receive a dividend of €0.61. Ex-date: 19th May 2024 Payment date: 30th May 2024 Dividend yield will be 3.2%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by earnings (50% earnings payout ratio) but not covered by cash flows (206% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Mar 02Full year 2023 earnings released: EPS: €1.23 (vs €1.53 in FY 2022)Full year 2023 results: EPS: €1.23 (down from €1.53 in FY 2022). Revenue: €1.44b (down 1.0% from FY 2022). Net income: €72.9m (down 19% from FY 2022). Profit margin: 5.0% (down from 6.2% in FY 2022). Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 3.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €19.43, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 18x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 58% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €10.43 per share.
Valuation Update With 7 Day Price Move • Dec 20Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €19.06, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 56% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.36 per share.
공시 • Nov 21+ 2 more updatesCorbion N.V. to Report Fiscal Year 2023 Results on Mar 01, 2024Corbion N.V. announced that they will report fiscal year 2023 results on Mar 01, 2024
Buying Opportunity • Oct 20Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be €21.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 8.1%. Revenue is forecast to grow by 7.1% in 2 years. Earnings is forecast to grow by 48% in the next 2 years.
Reported Earnings • Aug 11First half 2023 earnings released: EPS: €0.48 (vs €0.88 in 1H 2022)First half 2023 results: EPS: €0.48 (down from €0.88 in 1H 2022). Revenue: €738.0m (up 7.4% from 1H 2022). Net income: €28.1m (down 46% from 1H 2022). Profit margin: 3.8% (down from 7.5% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jun 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €21.63, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.24 per share.
공시 • May 18Corbion N.V. Approves Dividend for the Year 2022, Payable on 30 May 2023Corbion N.V. announced that General Shareholders Meeting held on 17 May 2023 approved dividend of €0.56 per ordinary share for the financial year 2022 was also approved. Dividends will be all-cash and will in principle be subject to Dutch dividend withholding tax of 15%. The ex-dividend date is 19 May 2023, the record date is 22 May 2023, and the payment day is 30 May 2023.
Upcoming Dividend • May 12Upcoming dividend of €0.56 per share at 1.9% yieldEligible shareholders must have bought the stock before 19 May 2023. Payment date: 30 May 2023. Payout ratio is a comfortable 37% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.3%).
Recent Insider Transactions • May 08Insider recently bought €142k worth of stockOn the 3rd of May, O.Y.A.R Rigaud bought around 5k shares on-market at roughly €28.37 per share. This transaction amounted to 5.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €259k more in shares than they have sold in the last 12 months.
Reported Earnings • Mar 04Full year 2022 earnings released: EPS: €1.53 (vs €1.33 in FY 2021)Full year 2022 results: EPS: €1.53 (up from €1.33 in FY 2021). Revenue: €1.46b (up 36% from FY 2021). Net income: €90.0m (up 15% from FY 2021). Profit margin: 6.2% (down from 7.3% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
공시 • Dec 13+ 1 more updateCorbion N.V. to Report Fiscal Year 2022 Results on Mar 03, 2023Corbion N.V. announced that they will report fiscal year 2022 results on Mar 03, 2023
Buying Opportunity • Oct 05Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €32.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.4% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 17% in 2 years. Earnings is forecast to grow by 59% in the next 2 years.
Buying Opportunity • Sep 20Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be €32.35, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.4% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 16% in 2 years. Earnings is forecast to grow by 59% in the next 2 years.
Reported Earnings • Aug 11First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down €67.5m from profit in 1H 2021). Profit margin: (down from 13% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 7.9% compared to a 21% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jul 21Investor sentiment improved over the past weekAfter last week's 17% share price gain to €33.18, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 18x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €35.74 per share.
Buying Opportunity • Jul 05Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 9.2%. The fair value is estimated to be €35.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 9.3% per annum. Earnings is also forecast to grow by 9.9% per annum over the same time period.
Upcoming Dividend • May 13Upcoming dividend of €0.56 per shareEligible shareholders must have bought the stock before 20 May 2022. Payment date: 31 May 2022. Payout ratio is a comfortable 42% but the company is not cash flow positive. Trailing yield: 1.7%. Lower than top quartile of British dividend payers (4.8%). Lower than average of industry peers (2.7%).
Reported Earnings • Feb 26Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: €1.33 (up from €1.24 in FY 2020). Revenue: €1.07b (up 8.5% from FY 2020). Net income: €78.3m (up 7.1% from FY 2020). Profit margin: 7.3% (down from 7.4% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 11% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 13First half 2021 earnings released: EPS €1.15 (vs €0.42 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €515.6m (up 4.8% from 1H 2020). Net income: €67.5m (up 173% from 1H 2020). Profit margin: 13% (up from 5.0% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 19% per year.
Executive Departure • May 26Member of the Supervisory Board has left the companyOn the 19th of May, Jack de Kreij's tenure as Member of the Supervisory Board ended after 10.1 years in the role. We don't have any record of a personal shareholding under Jack's name. A total of 2 executives have left over the last 12 months.
Upcoming Dividend • May 14Upcoming dividend of €0.56 per shareEligible shareholders must have bought the stock before 21 May 2021. Payment date: 01 June 2021. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (4.1%). Lower than average of industry peers (1.6%).
Analyst Estimate Surprise Post Earnings • Mar 07Revenue misses expectationsRevenue missed analyst estimates by 0.6%. Over the next year, revenue is forecast to grow 1.9% compared to a 9.0% decline forecast for the Chemicals industry in the United Kingdom.
Reported Earnings • Mar 07Full year 2020 earnings released: EPS €1.24 (vs €0.44 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €986.5m (up 1.0% from FY 2019). Net income: €73.1m (up 183% from FY 2019). Profit margin: 7.4% (up from 2.6% in FY 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Jan 30New 90-day high: €48.10The company is up 23% from its price of €38.95 on 30 October 2020. The British market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €119 per share.
Is New 90 Day High Low • Jan 04New 90-day high: €46.80The company is up 10.0% from its price of €42.65 on 06 October 2020. The British market is also up 10.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €110 per share.
Is New 90 Day High Low • Dec 19New 90-day high: €46.05The company is up 25% from its price of €36.95 on 18 September 2020. The British market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €109 per share.
Is New 90 Day High Low • Dec 03New 90-day high: €44.10The company is up 20% from its price of €36.85 on 04 September 2020. The British market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €94.58 per share.
Is New 90 Day High Low • Sep 30New 90-day high: €39.45The company is up 22% from its price of €32.30 on 02 July 2020. The British market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.75 per share.